New research published in The BMJ indicates the introduction of low dose CT (LDCT) screening in 2013 coincided with improved survival and a shift toward diagnoses of stage I non–small cell lung cancer (NSCLC).
However, data also showed disparities in stage diagnoses persist between patient populations and increased efforts to improve access to the service is warranted.
Although the early detection of lung cancer is the most promising strategy to decrease mortality from the disease, and the use of LDCT can detect the cancer at an earlier stage, “skepticism about the effectiveness of such screening outside of rigorous clinical trial settings continues to exist in the medical community,” the researchers explained.
Read More: https://www.ajmc.com/view/real-world-data-show-benefits-of-increased-lung-cancer-screening-but-persistent-disparities